Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Strides Pharma Science Ltd

| Q3 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤3rd Feb 26

Summary : Strides Pharma achieved strong Q3 FY'26 results with improved profitability and diversified growth, driven by Ex-U.S. markets and strategic investments, despite U.S. market headwinds.

Management Perspective positive : Management expressed being "very happy with the result," "very, very pleased with the results," and "delighted to report that we continue to progress" on key metrics, calling it an "exceptional quarter."

Concall Report Analysis & Insights

Business Overview

  1. Q3 FY'26 revenue grew 3.6%, or 8.6% excluding institutional business.
  2. Gross margins reached over 60% in Q3, 59.8% overall, driven by business mix.
  3. Ex-U.S. markets contributed 47% of Q3 revenues, growing 20% year-on-year.
  4. Debt/EBITDA improved to 1.59x, with net debt reduced by Rs. 170 crores.
  5. Operational PAT grew 39% year-on-year to Rs. 128 crores, exceeding FY'25 full-year PAT.

Future Growth Prospects

  1. Targeting $400 million in U.S. revenue by FY'28 through dormant product relaunch and R&D investments.
  2. Ex-U.S. markets expected to mirror U.S. market size within two years.
  3. Investing in complex generics like control substances, nasal sprays, and 505(b)(2) programs.
  4. One nasal spray product filed with US FDA, two more expected in next two quarters.
  5. Focus on regulatory filings and execution to drive growth in emerging markets.

Management Insights

  1. Management is pleased with progress on profitability, geographical diversification, and balance sheet strength.
  2. Ex-U.S. markets show a structural shift, growing faster than anticipated.
  3. U.S. business strategy remains intact for long-term growth despite short-term muted performance.
  4. Peter Hardwick appointed CEO North American Business to drive sustainable growth.
  5. Nandini Matiyani appointed Executive VP of HR to strengthen global people capabilities.

Signs of Skepticism

  1. U.S. revenue has been flat for several quarters, yet management reiterates a $400 million FY'28 target without clear short-term drivers.
  2. Management is vague on specific timelines for control substance quota normalization and product launch impacts.
  3. Uncertainty regarding the specific benefits of the India-EU FTA for generics was noted.
  4. Management avoids specific product-wise details or future pricing trend predictions.

Risk Factors

  1. U.S. business growth muted due to delayed flu season and slower quota allocations.
  2. Increased competition in new U.S. product launches impacting market share.
  3. Access market revenue subdued due to reduced funding from large donor institutions.
  4. Price erosions are an inherent and ongoing risk in the generics business.
  5. Currency depreciation can negatively impact net debt figures.

Good To Know

  1. ESG score improved from 75 to 80, reflecting focus on responsible growth.
  2. New labor code implemented without any financial impact on the company.
  3. Net finance costs for the quarter were Rs. 39.7 crores.
  4. Effective tax rate expected to be in the 15-18% range for the year.
  5. Maintenance CAPEX is projected at Rs. 100-125 crores annually.

Key Drivers

  1. Ex-U.S. market growth and diversification.
  2. U.S. dormant product portfolio relaunch.
  3. Investments in complex generics pipeline.
  4. Continued balance sheet strength improvement.

Key Analyst Discussions

Competitive Environment

  1. Competition is an ongoing aspect of the generics business, not limited to new launches.
  2. Company focuses on balancing new product launches with market erosions from competition.

Market Trends & Consumer Behavior

  1. Delayed flu season in Q3 impacted U.S. seasonal sales.
  2. Price erosions are inherent in generics, compensated by COGS improvements.
  3. Management cannot predict if current pricing pressure trends will abate.

Financial Highlights

  1. Sustainable gross margin is expected to be in the 58-60% range.
  2. Debt restatements due to currency depreciation are reflected in P&L or balance sheet.
  3. Net debt stands at approximately $160 million.
  4. Operational cash flow for 9 months was Rs. 484 crores, about 70% of EBITDA.
  5. Operating expenses are well within range, supporting margin expansion.

Product Composition

  1. Eight unprofitable products were discontinued to maintain profitability thresholds.
  2. U.S. growth drivers include dormant products, control substances, and R&D programs.
  3. Product pipeline is focused on the generic space without specific therapeutic areas.

Strategic Considerations

  1. Ex-U.S. growth is driven by investments, regulatory strategy, portfolio maximization, and new partners.
  2. Company is expanding its portfolio in existing geographies, not entering new markets.
  3. Penetrating the European market is complex due to 28 countries and country-specific approvals.
  4. Nasal spray revenue is expected to kick in from 2027-2028.
  5. Access market order book is subdued due to reduced donor funding from large institutions.